Who are Anti-CD5 CAR NK cells's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Alemtuzumab infusion, Alemtuzumab (GZ402673), MabCampath-1h, FluCAM [Fludara + Campath], CAR T cells.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-cd5-car-nk-cells.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Anti-CD5 CAR NK cells — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-CD5 CAR NK cells (Anti-CD5 CAR NK cells) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CAR T cell therapy. Area: Oncology.

phase 1 CAR T cell therapy CD5 Oncology Biologic Live · refreshed every 30 min

Target snapshot

Anti-CD5 CAR NK cells (Anti-CD5 CAR NK cells) — Chongqing Precision Biotech Co., Ltd. Anti-CD5 CAR T cells target and kill cancer cells by binding to the CD5 receptor on their surface.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Anti-CD5 CAR NK cells TARGET	Anti-CD5 CAR NK cells	Chongqing Precision Biotech Co., Ltd	phase 1	CAR T cell therapy	CD5
Alemtuzumab infusion	Alemtuzumab infusion	Johns Hopkins University	marketed	monoclonal antibody (CD52-directed)	CD52
Alemtuzumab (GZ402673)	Alemtuzumab (GZ402673)	Genzyme, a Sanofi Company	marketed	Monoclonal antibody (CD52 antagonist)	CD52
MabCampath-1h	MabCampath-1h	University of British Columbia	phase 3	Monoclonal antibody (CD52 antagonist)	CD52
FluCAM [Fludara + Campath]	FluCAM [Fludara + Campath]	Genzyme, a Sanofi Company	phase 3	Combination chemotherapy and monoclonal antibody	Ribonucleotide reductase / DNA polymerase (fludarabine); CD52 (alemtuzumab)
CAR T cells	CAR T cells	Memorial Sloan Kettering Cancer Center	phase 3	CAR T cell therapy	Tumor-associated antigens (e.g., CD19, BCMA, mesothelin depending on construct)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CAR T cell therapy class)

AffyImmune Therapeutics, Inc. · 1 drug in this class
Allife Medical Science and Technology Co., Ltd. · 1 drug in this class
Chongqing Precision Biotech Co., Ltd · 1 drug in this class
Hebei Senlang Biotechnology Inc., Ltd. · 1 drug in this class
Memorial Sloan Kettering Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-CD5 CAR NK cells — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cd5-car-nk-cells. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab